Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04645355 · ClinicalTrials.gov registry record · Phase 4
Guselkumab Immunogenetics
A Phase 4 study of Plaque Psoriasis and Psoriasis Guttate, sponsored by University of California, San Francisco.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 25
- Enrollment target
- 1
- Study location
NCT04645355: Recruiting Phase 4 study of Plaque Psoriasis and Psoriasis Guttate, sponsored by University of California, San Francisco.
NCT04645355 is a Phase 4 study of Plaque Psoriasis and Psoriasis Guttate that is actively recruiting participants, run by University of California, San Francisco. The registered enrollment target is 25 participants, below the 415-participant average among 45 other Plaque Psoriasis trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04645355, a Phase 4 study of Plaque Psoriasis and Psoriasis Guttate, is actively recruiting participants, sponsored by University of California, San Francisco.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 25 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a two-arm open-label study to evaluate the clinical and immunogenetic responses of patients with plaque or guttate psoriasis to treatment with guselkumab.
Primary Outcome
Mean change from baseline in percent of lesional CD4+ T effector cells producing IL-17 between baseline and week 12
Conditions Studied
Interventions
- DRUG Guselkumab
Study Locations (1)
California
- UCSF Psoriasis and Skin Treatment Center - San Francisco
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2021-03-01 |
| Est. Completion | 2025-01-01 |
| Phase | Phase 4 |
What NCT04645355 shows while recruiting
NCT04645355 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 25 participants, a relatively small participant target, below the 415-participant average among 45 other Plaque Psoriasis trials with a reported enrollment target (94% lower).
The record links to 2 conditions, with Plaque Psoriasis appearing as the primary indexed condition, and to 1 intervention - of which Guselkumab is the first listed.
NCT04645355 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT04645355 about?
NCT04645355 is a clinical study titled "Guselkumab Immunogenetics". This is a two-arm open-label study to evaluate the clinical and immunogenetic responses of patients with plaque or guttate psoriasis to treatment with guselkumab.
What is the current status of trial NCT04645355?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 25 participants. The study started on 2021-03-01. Estimated completion is 2025-01-01.
What conditions does trial NCT04645355 study?
This clinical trial studies the following conditions: Plaque Psoriasis, Psoriasis Guttate.
What interventions are being tested in trial NCT04645355?
The interventions under investigation include: Guselkumab (DRUG).
Who is sponsoring clinical trial NCT04645355?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04645355 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Plaque Psoriasis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04645355's enrollment target sits among peer trials
25 41st of 45 higher than 4 of 45 other Plaque Psoriasis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Plaque Psoriasis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Bimekizumab in Plaque Psoriasis
RECRUITING · Phase 4
-
Patient Preference of Taclonex Ointment to Taclonex Scalp Suspension in Adult Subjects With Psoriasis Vulgaris
COMPLETED · Phase 4
-
Adrenal Suppression and Absorption Study of Halobetasol Propionate Foam in Subjects 12-17 With Plaque Psoriasis
COMPLETED · Phase 4
-
Patient Satisfaction Following Twice Daily Dosing With DFD-01 in Subjects With Moderate Plaque Psoriasis
COMPLETED · Phase 4
-
Subject Reported Target-lesion Numeric Rating Scale Evaluation by Subjects With Plaque Psoriasis Treated With Clobex® (Clobetasol Propionate) Spray 0.05%
COMPLETED · Phase 4
-
Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01166854 · 25 participants
Characterization of Familial Myopathy and Paget Disease of Bone
- NCT01913106 · 25 participants · Phase 1
HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer
- NCT02138669 · 25 participants · NA
Intacs Prescription Inserts for Keratoconus Patients
- NCT02174549 · 25 participants · Phase 1
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI